Interleukin-2 – induced vascular leak syndrome: clinically relevant in vitro recapitulation with a patient-derived lung-on-chip

Author(s):  
Giulia Raggi ◽  
Nuria Roldan ◽  
Virginie Micallef ◽  
Aude Rapet ◽  
Lea De Maddalena ◽  
...  
2002 ◽  
Vol 25 (6) ◽  
pp. 476-488 ◽  
Author(s):  
Amjad Mustafa ◽  
Robert J. McKallip ◽  
Michael Fisher ◽  
Robert Duncan ◽  
Prakash S. Nagarkatti ◽  
...  

1994 ◽  
Vol 22 (4) ◽  
pp. 381-397 ◽  
Author(s):  
Shinsuke Fujita ◽  
Raj Puri ◽  
Zu-Xi Yu ◽  
William Travis ◽  
Maria Yamaguchi ◽  
...  

Blood ◽  
1997 ◽  
Vol 90 (6) ◽  
pp. 2323-2334 ◽  
Author(s):  
Alan L. Lindstrom ◽  
Stanley L. Erlandsen ◽  
John H. Kersey ◽  
Christopher A. Pennell

Abstract Vascular leak syndrome (VLS) is the dose-limiting toxicity observed in clinical trials of immunotoxins containing ricin toxin A chain (RTA). RTA itself is thought to cause VLS by damaging vascular endothelial cells, but the exact mechanism remains unclear. This is partially due to the paucity of appropriate models. To study VLS, we developed an in vitro model in which human umbilical vein-derived endothelial cells were first grown to confluence on microporous supports and then cultured under low pressure in the presence or absence of RTA. Endothelial cell barrier function was assessed by measuring the volume of fluid that passed through each monolayer per unit time. We found that RTA significantly increased monolayer permeability at times and concentrations consistent with the onset of VLS in patients treated with RTA-based immunotoxins. Scanning electron microscopy showed that intercellular gaps formed in endothelial monolayers exposed to RTA. Intercellular gap formation followed endothelial cell death caused by the enzymatic activity of RTA. We conclude that RTA is directly toxic to endothelial cells in vitro and speculate that this contributes to VLS in vivo.


2005 ◽  
Vol 42 (4) ◽  
pp. 187-193 ◽  
Author(s):  
Stephen C. Hornyak ◽  
Diana M. Orentas ◽  
Linda M. Karavodin ◽  
Kurt R. Gehlsen

2012 ◽  
Vol 206 (1) ◽  
pp. S109
Author(s):  
Mohammad Uddin ◽  
Steven Allen ◽  
Richard Jones ◽  
David Zawieja ◽  
Thomas Kuehl

Blood ◽  
1997 ◽  
Vol 90 (6) ◽  
pp. 2323-2334 ◽  
Author(s):  
Alan L. Lindstrom ◽  
Stanley L. Erlandsen ◽  
John H. Kersey ◽  
Christopher A. Pennell

Vascular leak syndrome (VLS) is the dose-limiting toxicity observed in clinical trials of immunotoxins containing ricin toxin A chain (RTA). RTA itself is thought to cause VLS by damaging vascular endothelial cells, but the exact mechanism remains unclear. This is partially due to the paucity of appropriate models. To study VLS, we developed an in vitro model in which human umbilical vein-derived endothelial cells were first grown to confluence on microporous supports and then cultured under low pressure in the presence or absence of RTA. Endothelial cell barrier function was assessed by measuring the volume of fluid that passed through each monolayer per unit time. We found that RTA significantly increased monolayer permeability at times and concentrations consistent with the onset of VLS in patients treated with RTA-based immunotoxins. Scanning electron microscopy showed that intercellular gaps formed in endothelial monolayers exposed to RTA. Intercellular gap formation followed endothelial cell death caused by the enzymatic activity of RTA. We conclude that RTA is directly toxic to endothelial cells in vitro and speculate that this contributes to VLS in vivo.


Sign in / Sign up

Export Citation Format

Share Document